Morningstar - SKYCITY Entertainment Group Limited (SKC) New Convention Centre Should Boost SkyCitys Earnings Growth in the Medium Term

Report

Morningstar

Daniel Ragonese

EUR 100.00 For Business Accounts Only

New Convention Centre Should Boost SkyCity's Earnings Growth in the Medium Term

Narrow-moat-rated SkyCity Entertainment started the year on a positive note, reporting fiscal 2019 interim normalised NPAT of NZD 97 million, an 11% increase on the previous corresponding period, or pcp. The result was driven by strong performance in Auckland and International VIP, which collectively make up around 80% of group EBITDA. Management guided to around 5% growth in normalised EBITDA during fiscal 2019 (assuming the sale of the Darwin casino settles on June 30, 2019), which is marginal...

06/05/2019 13 EN

Underlying

SKYCITY Entertainment Group Limited

Sky City Entertainment Group and its subsidiaries are organised into the following main operating segments: SKYCITY Auckland, which includes casino operations, hotels and convention, food and beverage, carparking, Sky Tower and a number of other related activities; Rest of New Zealand, which includes the Group's interest in SKYCITY Hamilton, SKYCITY Queenstown Casino and SKYCITY Wharf; SKYCITY Adelaide, which includes casino operations and food and beverage; SKYCITY Darwin, which includes casino operations, food and beverage and hotel; as well as International Business, which includes commission and complimentary play.

See profile

NZSKCE0001S2 NZX New Zealand

Provider

Morningstar

Morningstar, Inc. is a leading provider of independent investment research in North America, Europe, Australia, and Asia. The company offer an extensive line of products and services for individual investors, financial advisors, asset managers, and retirement plan providers and sponsors.

Morningstar provides data on approximately 530,000 investment offerings, including stocks, mutual funds, and similar vehicles, along with real-time global market data on more than 18 million equities, indexes, futures, options, commodities, and precious metals, in addition to foreign exchange and Treasury markets. Morningstar also offers investment management services through its investment advisory subsidiaries and had approximately $185 billion in assets under advisement and management as of June 30, 2016.

We have operations in 27 countries.

See profile

Analysts

Daniel Ragonese

Other Reports on these Companies

SmartInsider

SkyCity Entertainment Group Limited: 1 director

A director at SkyCity Entertainment Group Limited bought 33,000 shares at 1.930NZD and the significance rating of the trade was 69/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules...

Free Trial

March 7, 2024 March 7, 2024 1 EN

TheScreener

SKY CITY ENTER sees an upgrade to Slightly Positive due to a better fundamental star rating

The general evaluation of SKY CITY ENTER (AU), a company active in the Recreational Services industry, has been upgraded by the independent financial analyst theScreener with the addition of a star. Its fundamental valuation now shows 4 out of 4 possible stars while its market behaviour can be considered as moderately risky. theScreener believes that the additional star(s) merits the upgrade of its general evaluation to Slightly Positive. As of the analysis date February 8, 2022, the closing price was AUD 2.87 and its potential was estimated at AUD 3.16.

Free Trial

February 9, 2022 February 9, 2022 1 EN

TheScreener

SKY CITY ENTER reduced its risk exposure resulting in an upgrade to Slightly Positive

SKY CITY ENTER (NZ), a company active in the Gambling industry, reduced its market risk and raised its general evaluation. The independent financial analyst theScreener awarded an improved star rating to the company, which now shows 2 out of 4 possible stars; its market behaviour has improved and can be considered as defensive. theScreener believes that this new assessment merits an overall rating upgrade to Slightly Positive. As of the analysis date November 19, 2021, the closing price was NZD 3.22 and its potential was estimated at NZD 3.57.

Free Trial

November 20, 2021 November 20, 2021 6 EN

Business as Usual for No-Moat Lonza; Specialty Ingredients Carve-Out on Track for 2020

Contract manufacturer Lonza reported solid half-year results, with over CHF 2.9 billion in total sales year to date, up about 6.4% from last year and boosted by foreign exchange tailwinds. Core EBITDA margin expanded 30 basis points from last year to about 27.8%, helped slightly by new accounting standards. Management indicated that it continues to expect mid- to high-single-digit sales growth in 2019. We are maintaining our fair value estimate of CHF 210 per share and our no-moat rating. The ph...

EUR 100.00

July 25, 2019 July 25, 2019 13 EN

Joe Gemino

Joe Gemino

Sasol Provides Full-Year Production Update

No-moat Sasol provided an update on its full-year fiscal 2019 production metrics that included relatively stable liquids production. For the full year ended June 30, Sasol produced 1,470 thousand barrels of crude oil and condensate a day compared with 1,469 mboe/d in the year-ago period. However, declines continued with the companyâ€™s natural gas production, down 4% to 130.3 billion cubic feet compared with the period ended June 30, 2018. Sasol also reported flat refined products of 31.4 mmboe/d ...

EUR 100.00

July 25, 2019 July 25, 2019 12 EN

Damien Conover

Damien Conover

Astra Posts Solid 2Q, Driven by Strong Cancer Drug Sales and Moving Away From One-Time Divestments

We don't expect any major changes to our AstraZeneca fair value estimate following second-quarter results that largely fell in line with our expectations and slightly ahead of consensus expectations. Overall, the company is posting leading Big Pharma sales growth with total sales up 18% operationally year over year, led by impressive cancer drug sales growth of 57%. Astra's ability to continue to bring next generation drugs to the market that address unmet medical need (especially in oncology) s...

EUR 100.00

July 25, 2019 July 25, 2019 14 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

New Convention Centre Should Boost SkyCity's Earnings Growth in the Medium Term

SkyCity Entertainment Group Limited: 1 director

SKY CITY ENTER sees an upgrade to Slightly Positive due to a better fundamental star rating

SKY CITY ENTER reduced its risk exposure resulting in an upgrade to Slightly Positive

Business as Usual for No-Moat Lonza; Specialty Ingredients Carve-Out on Track for 2020

Sasol Provides Full-Year Production Update

Astra Posts Solid 2Q, Driven by Strong Cancer Drug Sales and Moving Away From One-Time Divestments

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe